提尔泽帕提德会影响女性的性功能:案例报告
Ghada Farouk Mohammed1, Mohammed Saleh Al-Dhubaibi2, Saleh Salem Bahaj3
1Department of Dermatology, Venereology and Sexology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Clinical medicine insights. Case reports
|June 9, 2025
概括
蒂尔泽帕提德是一种双GIP/GLP-1受体激动剂,可能会导致一些患者的性功能障碍. 症状在停止治疗后消失,并在重新开始治疗时重新出现,这表明需要进一步调查的与药物相关的效应.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 性医学性医学性医学性医学
背景情况:
- 蒂尔泽帕提德是一种新型的双双依赖葡萄糖的胰岛素型多 (GIP) 和葡萄糖类-1 (GLP-1) 受体激动剂,已被批准用于血糖控制.
- 虽然对体重控制和2型糖尿病有效,但其对性功能潜在的不良影响尚未得到充分证实.
研究的目的:
- 报告一个肥胖的女性患者的性功能障碍病例,该患者接受了提尔泽帕提德治疗.
- 评估蒂尔泽帕提德治疗与性功能障碍症状的出现和消失之间的关系.
主要方法:
- 进行了全面的临床评估,包括女性性功能指数 (FSFI).
- 通过实验室检测排除性功能障碍的其他潜在原因.
- 管理涉及生活方式的修改,盆地炼,布罗,滑剂和心理治疗,并进行纵向FSFI评分.
主要成果:
- 一名36岁的肥胖女性患者在提尔泽帕提德治疗期间出现了性欲下降,生殖器干燥和性欲不良 (FSFI=12.7).
- 在停止服用提尔泽帕提德后,症状显著改善 (FSFI=28.7),并在重新服用后复发 (FSFI=14.7).
- 在一个月的支持性治疗后,FSFI得分提高到24分.
结论:
- 蒂尔泽帕提德可能会对性功能产生不利影响,可能通过荷尔蒙或神经路径,尽管确切的机制尚不清楚.
- 多模式管理,包括性教育和治疗,对于在减肥治疗期间经历性功能障碍的患者至关重要.
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
221
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
221
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
132
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
132
01:23Antidepressant Drugs: MAOIs and Other Agents
200
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
200
01:20Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149